The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections
- PMID: 33184101
- DOI: 10.1183/13993003.02595-2020
The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections
Conflict of interest statement
Conflict of interest: E. Vallieres reports personal fees for lectures from AstraZeneca, personal fees for advisory board work from Regeneron, AbbVie and Oncocyte, personal fees for consultancy from Olympus, outside the submitted work.
Comment on
-
SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.Eur Respir J. 2020 Nov 12;56(5):2000118. doi: 10.1183/13993003.00118-2020. Print 2020 Nov. Eur Respir J. 2020. PMID: 32616595 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical